BACKGROUND: Killer immunoglobulin-like receptors (KIRs) bind human leukocyte antigen (HLA) class-I (HLA-I) ligands and regulate functions of natural killer cells and subsets of T cells. KIR/HLA-I interactions allow predicting natural killer cell alloreactivity in hematopoietic stem cell transplantation and in HLA-compatible kidney transplants, but its meaning in liver transplantation remains controversial. METHODS: KIR and HLA genotypes were studied in 402 liver transplants, using sequence-specific oligonucleotides and primer methods. Recipients and donor KIRs, HLA-C genotypes, KIR gene mismatches (MMs) between recipient-donor pairs, and KIR/HLA-ligand combinations were analyzed in overall transplantations, in the acute rejection (AR; n=110) and non-AR (n=292) groups. RESULTS: KIR gene MMs between recipients and donors, mainly in activating KIRs, and KIR2DL3 and KIR2DS1 of recipients in the presence of donor C2 ligands, significantly enhanced early AR rate (P<0.05), with KIR2DL3 and KIR2DS1 exhibiting a synergic effect in dependence of the donor C2 ligand number (χ2=7.662, P=0.022). KIR2DL3, KIR2DS1, and also KIR2DS4 significantly influenced short-term graft survival, with a benefit for transplantations combining KIR2DL3 recipients and donors having C1 ligands (log rank, P<0.019 at 1 year; hazards ratio [HR], 0.321; 95% confidence interval [CI], 0.107-0.962; P=0.042), whereas KIR2DS1 and KIR2DS4 recipients combined with donors lacking C1 ligands (C2/C2) exhibited a worse graft survival (log rank, P=0.035 at 6 months; HR, 7.713; 95% CI, 2.156-27.369; P=0.002 for KIR2DS1; and log rank, P=0.006 at 1 year; HR, 3.794; 95% CI, 1.267-11.365; P=0.017 for KIR2DS4). CONCLUSIONS: This study shows that KIR gene-gene MMs increase AR and that KIRs/C ligands associated to AR and KIR2DS4/C ligands also influence short-term graft survival.
BACKGROUND: Killer immunoglobulin-like receptors (KIRs) bind human leukocyte antigen (HLA) class-I (HLA-I) ligands and regulate functions of natural killer cells and subsets of T cells. KIR/HLA-I interactions allow predicting natural killer cell alloreactivity in hematopoietic stem cell transplantation and in HLA-compatible kidney transplants, but its meaning in liver transplantation remains controversial. METHODS:KIR and HLA genotypes were studied in 402 liver transplants, using sequence-specific oligonucleotides and primer methods. Recipients and donor KIRs, HLA-C genotypes, KIR gene mismatches (MMs) between recipient-donor pairs, and KIR/HLA-ligand combinations were analyzed in overall transplantations, in the acute rejection (AR; n=110) and non-AR (n=292) groups. RESULTS:KIR gene MMs between recipients and donors, mainly in activating KIRs, and KIR2DL3 and KIR2DS1 of recipients in the presence of donor C2 ligands, significantly enhanced early AR rate (P<0.05), with KIR2DL3 and KIR2DS1 exhibiting a synergic effect in dependence of the donor C2 ligand number (χ2=7.662, P=0.022). KIR2DL3, KIR2DS1, and also KIR2DS4 significantly influenced short-term graft survival, with a benefit for transplantations combining KIR2DL3 recipients and donors having C1 ligands (log rank, P<0.019 at 1 year; hazards ratio [HR], 0.321; 95% confidence interval [CI], 0.107-0.962; P=0.042), whereas KIR2DS1 and KIR2DS4 recipients combined with donors lacking C1 ligands (C2/C2) exhibited a worse graft survival (log rank, P=0.035 at 6 months; HR, 7.713; 95% CI, 2.156-27.369; P=0.002 for KIR2DS1; and log rank, P=0.006 at 1 year; HR, 3.794; 95% CI, 1.267-11.365; P=0.017 for KIR2DS4). CONCLUSIONS: This study shows that KIR gene-gene MMs increase AR and that KIRs/C ligands associated to AR and KIR2DS4/C ligands also influence short-term graft survival.
Authors: Trent M Prall; Michael E Graham; Julie A Karl; Roger W Wiseman; Adam J Ericsen; Muthuswamy Raveendran; R Alan Harris; Donna M Muzny; Richard A Gibbs; Jeffrey Rogers; David H O'Connor Journal: Immunogenetics Date: 2017-03-25 Impact factor: 2.846
Authors: A Podhorzer; N Paladino; M L Cuarterolo; H A Fainboim; S Paz; G Theiler; M Capucchio; S I López; A Machicote; S Montal; G Podesta; L Fainboim Journal: Genes Immun Date: 2016-02-18 Impact factor: 2.676
Authors: María V Martínez-Sánchez; Adela Periago; Isabel Legaz; Lourdes Gimeno; Anna Mrowiec; Natividad R Montes-Barqueros; José A Campillo; José M Bolarin; María V Bernardo; María R López-Álvarez; Consuelo González; María C García-Garay; Manuel Muro; Valentin Cabañas-Perianes; Jose L Fuster; Ana M García-Alonso; José M Moraleda; María R Álvarez-Lopez; Alfredo Minguela Journal: Oncoimmunology Date: 2015-10-29 Impact factor: 8.110
Authors: Isabel Legaz; Jose Miguel Bolarín; Elena Navarro; Jose Antonio Campillo; Rosa Moya; María Dolores Pérez-Cárceles; Aurelio Luna; Eduardo Osuna; Manuel Miras; Manuel Muro; Alfredo Minguela; Rocio Alvarez López Journal: Arch Med Sci Date: 2019-04-09 Impact factor: 3.318
Authors: Isabel Legaz; Jose M Bolarin; Jose A Campillo; Rosa M Moya; Aurelio Luna; Eduardo Osuna; Alfredo Minguela; Francisco Sanchez-Bueno; Maria Rocio Alvarez; Manuel Muro Journal: Arch Med Sci Date: 2019-06-18 Impact factor: 3.318
Authors: Valli De Re; Laura Caggiari; Mariangela De Zorzi; Ombretta Repetto; Anna Linda Zignego; Francesco Izzo; Maria Lina Tornesello; Franco Maria Buonaguro; Alessandra Mangia; Domenico Sansonno; Vito Racanelli; Salvatore De Vita; Pietro Pioltelli; Emanuela Vaccher; Massimiliano Berretta; Massimiliano Beretta; Cesare Mazzaro; Massimo Libra; Andrea Gini; Antonella Zucchetto; Renato Cannizzaro; Paolo De Paoli Journal: PLoS One Date: 2015-02-20 Impact factor: 3.240
Authors: Bjarte Fosby; Sigrid Næss; Johannes R Hov; James Traherne; Kirsten M Boberg; John Trowsdale; Aksel Foss; Pål-Dag Line; Andre Franke; Espen Melum; Helge Scott; Tom H Karlsen Journal: World J Gastroenterol Date: 2014-04-14 Impact factor: 5.742
Authors: F Boix; I Legaz; A Minhas; R Alfaro; V Jiménez-Coll; A Mrowiec; H Martínez-Banaclocha; J A Galián; C Botella; M R Moya-Quiles; F Sanchez-Bueno; R Robles; J de la Peña-Moral; P Ramirez; J A Pons; A Minguela; M Muro Journal: Clin Exp Immunol Date: 2020-10-29 Impact factor: 4.330